93A7AA5D-FA07-470A-9FD3-306EA577D3C4
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 24.21156373193167
- age_years
- 60
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.666
- E2F_TARGETS+0.594
- MYC_TARGETS_V1+0.593
- MYC_TARGETS_V2+0.593
- INTERFERON_GAMMA_RESPONSE+0.540
- DNA_REPAIR+0.529
- G2M_CHECKPOINT+0.516
- UNFOLDED_PROTEIN_RESPONSE+0.495
- OXIDATIVE_PHOSPHORYLATION+0.424
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.415
Top 10 suppressed
- KRAS_SIGNALING_DN-0.379
- SPERMATOGENESIS-0.293
- MYOGENESIS-0.206
- BILE_ACID_METABOLISM-0.181
- PANCREAS_BETA_CELLS-0.133
- ESTROGEN_RESPONSE_EARLY-0.117
- HEDGEHOG_SIGNALING-0.058
- UV_RESPONSE_DN-0.057
- APICAL_SURFACE-0.052
- ESTROGEN_RESPONSE_LATE-0.041
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C14BEAAE-A766-4ADE-A9B4-674D8717591F | — | — | 0.970 |
| 2 | EB8F7B74-694A-4F9F-9C0B-F04006033CA4 | — | — | 0.970 |
| 3 | D9385661-DBBA-4AF7-B7E6-857BF84CF7CD | — | — | 0.966 |
| 4 | BB96C5BA-CA50-40B4-B22A-3FCFE46AB11C | — | — | 0.965 |
| 5 | 6B8CAF74-45C6-4C20-8126-A99F73346198 | — | — | 0.964 |
| 6 | 6D1D9992-DA2B-419A-A80A-9EBCDA831754 | — | — | 0.963 |
| 7 | 94640BD8-E1D9-482D-A597-4790F6EEA6B7 | — | — | 0.961 |
| 8 | EC1C727A-1F71-4C09-B867-7F163424D463 | — | — | 0.961 |
| 9 | 7876A884-F031-42AB-ADC0-89589760FB6B | — | — | 0.960 |
| 10 | 9BB12A25-E833-4055-8CEF-814EA5454F11 | — | — | 0.955 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.666 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.594 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.593 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.593 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.540 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.529 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.516 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.495 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.424 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.415 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.408 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.390 | Idelalisib | — uncovered |
| APOPTOSIS | 0.372 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.348 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.341 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.341 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.334 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.315 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.294 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.288 | Idelalisib | — uncovered |